Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | PRCP | P42785 | 8/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15058828 | 0.89 | KCNH2 (0.55) | OPRM1OPRD1KCNH2CYP3A4CYP2C9 | |
| SCHEMBL13070492 | 0.88 | KCNH2 (0.51) | OPRM1OPRD1KCNH2CYP3A4CYP2C9 | |
| SCHEMBL12160175 | 0.87 | CYP3A4 (0.59) | OPRM1OPRD1KCNH2CYP3A4CYP2C9 | |
| SCHEMBL14216848 | 0.87 | CYP3A4 (0.59) | OPRM1OPRD1KCNH2CYP3A4CYP2C9 | |
| SCHEMBL16499294 | 0.86 | PRCP (0.50) | KCNH2CYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL749667 | 0.86 | PRCP (0.50) | KCNH2CYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL203606 | 0.86 | CYP3A4 (0.59) | OPRM1OPRD1KCNH2CYP3A4CYP2C9 | |
| SCHEMBL15773821 | 0.86 | CYP3A4 (0.59) | OPRM1OPRD1KCNH2CYP3A4CYP2C9 | |
| SCHEMBL14985707 | 0.86 | CYP3A4 (0.59) | OPRM1OPRD1KCNH2CYP3A4CYP2C9 | |
| SCHEMBL15368457 | 0.85 | CYP3A4 (0.56) | OPRM1OPRD1KCNH2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | OPRM1 2511/4885OPRD1 2377/4885KCNH2 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.